// App-Quantinova.ai

: Luspatercept in Combination with Recombinant-Erythropoietin in MDS RS Patients: Stimulating Early and Late Erythropoiesis

Researchers

Presenter

  • Francesco Versino

Principal Investigators

  • Marta Bortolotti

  • Beatrice Ferrari

  • Lorenzo Rizzo

  • Federico Mazzon

  • Marta Riva

  • Paola Bianchi

  • Wilma Barcellini

  • Bruno Fattizzo

Medical Centers

  • Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy

  • Hematology Unit, Pathophysiology of Anemias Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

  • Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, Milano, Italy

  • ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy

Locations

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Anemia

Biomarkers

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

  • TIMP Metallopeptidase Inhibitor 1

  • Red Blood Cells

  • Splicing Factor 3b Subunit 1

Drug/Treatment

  • Recombinant human erythropoietin

  • luspatercept

  • Erythropoietin

Outcome

  • N/A

Study Design

  • Multinational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved